nodes	percent_of_prediction	percent_of_DWPC	metapath
Metronidazole—CYP2C9—Teniposide—lymphatic system cancer	0.168	0.35	CbGbCtD
Metronidazole—CYP3A4—Cytarabine—lymphatic system cancer	0.0992	0.207	CbGbCtD
Metronidazole—CYP3A4—Teniposide—lymphatic system cancer	0.0977	0.203	CbGbCtD
Metronidazole—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0683	0.142	CbGbCtD
Metronidazole—CYP3A4—Vincristine—lymphatic system cancer	0.047	0.0979	CbGbCtD
Metronidazole—Hypersensitivity—Teniposide—lymphatic system cancer	0.000901	0.00173	CcSEcCtD
Metronidazole—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000901	0.00173	CcSEcCtD
Metronidazole—Flushing—Carmustine—lymphatic system cancer	0.000899	0.00173	CcSEcCtD
Metronidazole—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000894	0.00172	CcSEcCtD
Metronidazole—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.000894	0.00172	CcSEcCtD
Metronidazole—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000886	0.00171	CcSEcCtD
Metronidazole—Asthenia—Teniposide—lymphatic system cancer	0.000878	0.00169	CcSEcCtD
Metronidazole—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.000873	0.00168	CcSEcCtD
Metronidazole—Malaise—Bleomycin—lymphatic system cancer	0.000871	0.00168	CcSEcCtD
Metronidazole—Pruritus—Teniposide—lymphatic system cancer	0.000866	0.00167	CcSEcCtD
Metronidazole—Leukopenia—Bleomycin—lymphatic system cancer	0.000865	0.00166	CcSEcCtD
Metronidazole—Cystitis—Methotrexate—lymphatic system cancer	0.000863	0.00166	CcSEcCtD
Metronidazole—Cardiac disorder—Vincristine—lymphatic system cancer	0.000858	0.00165	CcSEcCtD
Metronidazole—Skin exfoliation—Methotrexate—lymphatic system cancer	0.000853	0.00164	CcSEcCtD
Metronidazole—Body temperature increased—Fludarabine—lymphatic system cancer	0.00085	0.00164	CcSEcCtD
Metronidazole—Mental disorder—Carmustine—lymphatic system cancer	0.000849	0.00163	CcSEcCtD
Metronidazole—Vaginal infection—Methotrexate—lymphatic system cancer	0.000844	0.00162	CcSEcCtD
Metronidazole—Erythema—Carmustine—lymphatic system cancer	0.000843	0.00162	CcSEcCtD
Metronidazole—Angiopathy—Vincristine—lymphatic system cancer	0.000839	0.00161	CcSEcCtD
Metronidazole—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.000839	0.00161	CcSEcCtD
Metronidazole—Diarrhoea—Teniposide—lymphatic system cancer	0.000837	0.00161	CcSEcCtD
Metronidazole—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000833	0.0016	CcSEcCtD
Metronidazole—Chest pain—Bleomycin—lymphatic system cancer	0.000822	0.00158	CcSEcCtD
Metronidazole—Back pain—Carmustine—lymphatic system cancer	0.000816	0.00157	CcSEcCtD
Metronidazole—Mental disorder—Vincristine—lymphatic system cancer	0.00081	0.00156	CcSEcCtD
Metronidazole—Neoplasm—Methotrexate—lymphatic system cancer	0.000808	0.00155	CcSEcCtD
Metronidazole—Bladder pain—Methotrexate—lymphatic system cancer	0.000808	0.00155	CcSEcCtD
Metronidazole—Urine output increased—Methotrexate—lymphatic system cancer	0.000808	0.00155	CcSEcCtD
Metronidazole—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000799	0.00154	CcSEcCtD
Metronidazole—Confusional state—Bleomycin—lymphatic system cancer	0.000795	0.00153	CcSEcCtD
Metronidazole—Vision blurred—Carmustine—lymphatic system cancer	0.000795	0.00153	CcSEcCtD
Metronidazole—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000792	0.00152	CcSEcCtD
Metronidazole—Tremor—Carmustine—lymphatic system cancer	0.00079	0.00152	CcSEcCtD
Metronidazole—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000788	0.00152	CcSEcCtD
Metronidazole—Oedema—Bleomycin—lymphatic system cancer	0.000788	0.00152	CcSEcCtD
Metronidazole—Erythema—Mitoxantrone—lymphatic system cancer	0.000784	0.00151	CcSEcCtD
Metronidazole—Infection—Bleomycin—lymphatic system cancer	0.000783	0.00151	CcSEcCtD
Metronidazole—Back pain—Vincristine—lymphatic system cancer	0.000779	0.0015	CcSEcCtD
Metronidazole—Vomiting—Teniposide—lymphatic system cancer	0.000778	0.0015	CcSEcCtD
Metronidazole—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000772	0.00149	CcSEcCtD
Metronidazole—Asthenia—Fludarabine—lymphatic system cancer	0.000772	0.00148	CcSEcCtD
Metronidazole—Rash—Teniposide—lymphatic system cancer	0.000771	0.00148	CcSEcCtD
Metronidazole—Dermatitis—Teniposide—lymphatic system cancer	0.000771	0.00148	CcSEcCtD
Metronidazole—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000768	0.00148	CcSEcCtD
Metronidazole—Headache—Teniposide—lymphatic system cancer	0.000766	0.00147	CcSEcCtD
Metronidazole—Pruritus—Fludarabine—lymphatic system cancer	0.000761	0.00146	CcSEcCtD
Metronidazole—Back pain—Mitoxantrone—lymphatic system cancer	0.000758	0.00146	CcSEcCtD
Metronidazole—Leukopenia—Carmustine—lymphatic system cancer	0.000755	0.00145	CcSEcCtD
Metronidazole—Anorexia—Bleomycin—lymphatic system cancer	0.000752	0.00145	CcSEcCtD
Metronidazole—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000749	0.00144	CcSEcCtD
Metronidazole—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000739	0.00142	CcSEcCtD
Metronidazole—Photosensitivity—Methotrexate—lymphatic system cancer	0.000739	0.00142	CcSEcCtD
Metronidazole—Polyuria—Methotrexate—lymphatic system cancer	0.000739	0.00142	CcSEcCtD
Metronidazole—Diarrhoea—Fludarabine—lymphatic system cancer	0.000736	0.00142	CcSEcCtD
Metronidazole—Convulsion—Carmustine—lymphatic system cancer	0.000731	0.00141	CcSEcCtD
Metronidazole—Hypertension—Carmustine—lymphatic system cancer	0.000728	0.0014	CcSEcCtD
Metronidazole—Nausea—Teniposide—lymphatic system cancer	0.000727	0.0014	CcSEcCtD
Metronidazole—Vertigo—Vincristine—lymphatic system cancer	0.000723	0.00139	CcSEcCtD
Metronidazole—Hepatic failure—Methotrexate—lymphatic system cancer	0.000722	0.00139	CcSEcCtD
Metronidazole—Leukopenia—Vincristine—lymphatic system cancer	0.000721	0.00139	CcSEcCtD
Metronidazole—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000718	0.00138	CcSEcCtD
Metronidazole—Chest pain—Carmustine—lymphatic system cancer	0.000718	0.00138	CcSEcCtD
Metronidazole—Paraesthesia—Bleomycin—lymphatic system cancer	0.000708	0.00136	CcSEcCtD
Metronidazole—Malaise—Mitoxantrone—lymphatic system cancer	0.000707	0.00136	CcSEcCtD
Metronidazole—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000702	0.00135	CcSEcCtD
Metronidazole—Convulsion—Vincristine—lymphatic system cancer	0.000697	0.00134	CcSEcCtD
Metronidazole—Hypertension—Vincristine—lymphatic system cancer	0.000695	0.00134	CcSEcCtD
Metronidazole—Confusional state—Carmustine—lymphatic system cancer	0.000694	0.00134	CcSEcCtD
Metronidazole—Oedema—Carmustine—lymphatic system cancer	0.000688	0.00132	CcSEcCtD
Metronidazole—Decreased appetite—Bleomycin—lymphatic system cancer	0.000685	0.00132	CcSEcCtD
Metronidazole—Infection—Carmustine—lymphatic system cancer	0.000684	0.00132	CcSEcCtD
Metronidazole—Vomiting—Fludarabine—lymphatic system cancer	0.000684	0.00132	CcSEcCtD
Metronidazole—Convulsion—Mitoxantrone—lymphatic system cancer	0.000679	0.00131	CcSEcCtD
Metronidazole—Rash—Fludarabine—lymphatic system cancer	0.000678	0.0013	CcSEcCtD
Metronidazole—Dermatitis—Fludarabine—lymphatic system cancer	0.000677	0.0013	CcSEcCtD
Metronidazole—Hypertension—Mitoxantrone—lymphatic system cancer	0.000677	0.0013	CcSEcCtD
Metronidazole—Pain—Bleomycin—lymphatic system cancer	0.000674	0.0013	CcSEcCtD
Metronidazole—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000674	0.0013	CcSEcCtD
Metronidazole—Headache—Fludarabine—lymphatic system cancer	0.000674	0.0013	CcSEcCtD
Metronidazole—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000667	0.00128	CcSEcCtD
Metronidazole—Chest pain—Mitoxantrone—lymphatic system cancer	0.000667	0.00128	CcSEcCtD
Metronidazole—Oedema—Vincristine—lymphatic system cancer	0.000657	0.00126	CcSEcCtD
Metronidazole—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000657	0.00126	CcSEcCtD
Metronidazole—Anorexia—Carmustine—lymphatic system cancer	0.000656	0.00126	CcSEcCtD
Metronidazole—Infection—Vincristine—lymphatic system cancer	0.000653	0.00126	CcSEcCtD
Metronidazole—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00065	0.00125	CcSEcCtD
Metronidazole—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000649	0.00125	CcSEcCtD
Metronidazole—Confusional state—Mitoxantrone—lymphatic system cancer	0.000645	0.00124	CcSEcCtD
Metronidazole—Nervous system disorder—Vincristine—lymphatic system cancer	0.000644	0.00124	CcSEcCtD
Metronidazole—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000643	0.00124	CcSEcCtD
Metronidazole—Oedema—Mitoxantrone—lymphatic system cancer	0.00064	0.00123	CcSEcCtD
Metronidazole—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00064	0.00123	CcSEcCtD
Metronidazole—Nausea—Fludarabine—lymphatic system cancer	0.000639	0.00123	CcSEcCtD
Metronidazole—Infection—Mitoxantrone—lymphatic system cancer	0.000636	0.00122	CcSEcCtD
Metronidazole—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000635	0.00122	CcSEcCtD
Metronidazole—Shock—Mitoxantrone—lymphatic system cancer	0.000629	0.00121	CcSEcCtD
Metronidazole—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000627	0.00121	CcSEcCtD
Metronidazole—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000626	0.00121	CcSEcCtD
Metronidazole—Urticaria—Bleomycin—lymphatic system cancer	0.000626	0.00121	CcSEcCtD
Metronidazole—Anorexia—Vincristine—lymphatic system cancer	0.000626	0.0012	CcSEcCtD
Metronidazole—Body temperature increased—Bleomycin—lymphatic system cancer	0.000623	0.0012	CcSEcCtD
Metronidazole—Insomnia—Carmustine—lymphatic system cancer	0.000622	0.0012	CcSEcCtD
Metronidazole—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000621	0.0012	CcSEcCtD
Metronidazole—Irritability—Methotrexate—lymphatic system cancer	0.000619	0.00119	CcSEcCtD
Metronidazole—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000619	0.00119	CcSEcCtD
Metronidazole—Paraesthesia—Carmustine—lymphatic system cancer	0.000618	0.00119	CcSEcCtD
Metronidazole—Somnolence—Carmustine—lymphatic system cancer	0.000612	0.00118	CcSEcCtD
Metronidazole—Anorexia—Mitoxantrone—lymphatic system cancer	0.00061	0.00117	CcSEcCtD
Metronidazole—Ataxia—Methotrexate—lymphatic system cancer	0.00061	0.00117	CcSEcCtD
Metronidazole—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000599	0.00115	CcSEcCtD
Metronidazole—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000599	0.00115	CcSEcCtD
Metronidazole—Decreased appetite—Carmustine—lymphatic system cancer	0.000598	0.00115	CcSEcCtD
Metronidazole—Insomnia—Vincristine—lymphatic system cancer	0.000594	0.00114	CcSEcCtD
Metronidazole—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000594	0.00114	CcSEcCtD
Metronidazole—Paraesthesia—Vincristine—lymphatic system cancer	0.00059	0.00114	CcSEcCtD
Metronidazole—Pain—Carmustine—lymphatic system cancer	0.000589	0.00113	CcSEcCtD
Metronidazole—Constipation—Carmustine—lymphatic system cancer	0.000589	0.00113	CcSEcCtD
Metronidazole—Breast disorder—Methotrexate—lymphatic system cancer	0.000586	0.00113	CcSEcCtD
Metronidazole—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000584	0.00112	CcSEcCtD
Metronidazole—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000583	0.00112	CcSEcCtD
Metronidazole—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000581	0.00112	CcSEcCtD
Metronidazole—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000574	0.00111	CcSEcCtD
Metronidazole—Decreased appetite—Vincristine—lymphatic system cancer	0.000571	0.0011	CcSEcCtD
Metronidazole—Somnolence—Mitoxantrone—lymphatic system cancer	0.000569	0.00109	CcSEcCtD
Metronidazole—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000567	0.00109	CcSEcCtD
Metronidazole—Feeling abnormal—Carmustine—lymphatic system cancer	0.000567	0.00109	CcSEcCtD
Metronidazole—Fatigue—Vincristine—lymphatic system cancer	0.000566	0.00109	CcSEcCtD
Metronidazole—Asthenia—Bleomycin—lymphatic system cancer	0.000566	0.00109	CcSEcCtD
Metronidazole—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000563	0.00108	CcSEcCtD
Metronidazole—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000563	0.00108	CcSEcCtD
Metronidazole—Constipation—Vincristine—lymphatic system cancer	0.000562	0.00108	CcSEcCtD
Metronidazole—Pain—Vincristine—lymphatic system cancer	0.000562	0.00108	CcSEcCtD
Metronidazole—Asthma—Methotrexate—lymphatic system cancer	0.000561	0.00108	CcSEcCtD
Metronidazole—Pruritus—Bleomycin—lymphatic system cancer	0.000558	0.00107	CcSEcCtD
Metronidazole—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000556	0.00107	CcSEcCtD
Metronidazole—Eosinophilia—Methotrexate—lymphatic system cancer	0.000555	0.00107	CcSEcCtD
Metronidazole—Fatigue—Mitoxantrone—lymphatic system cancer	0.000552	0.00106	CcSEcCtD
Metronidazole—Pancreatitis—Methotrexate—lymphatic system cancer	0.00055	0.00106	CcSEcCtD
Metronidazole—Constipation—Mitoxantrone—lymphatic system cancer	0.000547	0.00105	CcSEcCtD
Metronidazole—Pain—Mitoxantrone—lymphatic system cancer	0.000547	0.00105	CcSEcCtD
Metronidazole—Abdominal pain—Carmustine—lymphatic system cancer	0.000544	0.00105	CcSEcCtD
Metronidazole—Body temperature increased—Carmustine—lymphatic system cancer	0.000544	0.00105	CcSEcCtD
Metronidazole—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000537	0.00103	CcSEcCtD
Metronidazole—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000537	0.00103	CcSEcCtD
Metronidazole—Pancytopenia—Methotrexate—lymphatic system cancer	0.000532	0.00102	CcSEcCtD
Metronidazole—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000527	0.00101	CcSEcCtD
Metronidazole—Dysuria—Methotrexate—lymphatic system cancer	0.000524	0.00101	CcSEcCtD
Metronidazole—Neutropenia—Methotrexate—lymphatic system cancer	0.000524	0.00101	CcSEcCtD
Metronidazole—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000523	0.00101	CcSEcCtD
Metronidazole—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000521	0.001	CcSEcCtD
Metronidazole—Abdominal pain—Vincristine—lymphatic system cancer	0.000519	0.000999	CcSEcCtD
Metronidazole—Body temperature increased—Vincristine—lymphatic system cancer	0.000519	0.000999	CcSEcCtD
Metronidazole—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000512	0.000985	CcSEcCtD
Metronidazole—Urticaria—Mitoxantrone—lymphatic system cancer	0.000508	0.000978	CcSEcCtD
Metronidazole—Hypersensitivity—Carmustine—lymphatic system cancer	0.000507	0.000976	CcSEcCtD
Metronidazole—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000506	0.000973	CcSEcCtD
Metronidazole—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000506	0.000973	CcSEcCtD
Metronidazole—Vomiting—Bleomycin—lymphatic system cancer	0.000501	0.000965	CcSEcCtD
Metronidazole—Infestation NOS—Methotrexate—lymphatic system cancer	0.0005	0.000962	CcSEcCtD
Metronidazole—Infestation—Methotrexate—lymphatic system cancer	0.0005	0.000962	CcSEcCtD
Metronidazole—Drowsiness—Methotrexate—lymphatic system cancer	0.0005	0.000962	CcSEcCtD
Metronidazole—Depression—Methotrexate—lymphatic system cancer	0.000498	0.000959	CcSEcCtD
Metronidazole—Rash—Bleomycin—lymphatic system cancer	0.000497	0.000957	CcSEcCtD
Metronidazole—Dermatitis—Bleomycin—lymphatic system cancer	0.000497	0.000956	CcSEcCtD
Metronidazole—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000496	0.000953	CcSEcCtD
Metronidazole—Asthenia—Carmustine—lymphatic system cancer	0.000494	0.00095	CcSEcCtD
Metronidazole—Stomatitis—Methotrexate—lymphatic system cancer	0.000487	0.000937	CcSEcCtD
Metronidazole—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000486	0.000935	CcSEcCtD
Metronidazole—Hypersensitivity—Vincristine—lymphatic system cancer	0.000484	0.000931	CcSEcCtD
Metronidazole—Sweating—Methotrexate—lymphatic system cancer	0.000479	0.000922	CcSEcCtD
Metronidazole—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000473	0.00091	CcSEcCtD
Metronidazole—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000471	0.000907	CcSEcCtD
Metronidazole—Asthenia—Vincristine—lymphatic system cancer	0.000471	0.000907	CcSEcCtD
Metronidazole—Diarrhoea—Carmustine—lymphatic system cancer	0.000471	0.000906	CcSEcCtD
Metronidazole—Nausea—Bleomycin—lymphatic system cancer	0.000468	0.000901	CcSEcCtD
Metronidazole—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000466	0.000897	CcSEcCtD
Metronidazole—Asthenia—Mitoxantrone—lymphatic system cancer	0.000459	0.000883	CcSEcCtD
Metronidazole—Dizziness—Carmustine—lymphatic system cancer	0.000455	0.000876	CcSEcCtD
Metronidazole—Diarrhoea—Vincristine—lymphatic system cancer	0.000449	0.000865	CcSEcCtD
Metronidazole—Hepatitis—Methotrexate—lymphatic system cancer	0.000449	0.000863	CcSEcCtD
Metronidazole—Pharyngitis—Methotrexate—lymphatic system cancer	0.000445	0.000857	CcSEcCtD
Metronidazole—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000438	0.000842	CcSEcCtD
Metronidazole—Vomiting—Carmustine—lymphatic system cancer	0.000438	0.000842	CcSEcCtD
Metronidazole—Dizziness—Vincristine—lymphatic system cancer	0.000434	0.000836	CcSEcCtD
Metronidazole—Rash—Carmustine—lymphatic system cancer	0.000434	0.000835	CcSEcCtD
Metronidazole—Dermatitis—Carmustine—lymphatic system cancer	0.000434	0.000834	CcSEcCtD
Metronidazole—Visual impairment—Methotrexate—lymphatic system cancer	0.000432	0.000832	CcSEcCtD
Metronidazole—Headache—Carmustine—lymphatic system cancer	0.000431	0.00083	CcSEcCtD
Metronidazole—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000424	0.000816	CcSEcCtD
Metronidazole—Eye disorder—Methotrexate—lymphatic system cancer	0.000419	0.000807	CcSEcCtD
Metronidazole—Tinnitus—Methotrexate—lymphatic system cancer	0.000418	0.000805	CcSEcCtD
Metronidazole—Vomiting—Vincristine—lymphatic system cancer	0.000418	0.000804	CcSEcCtD
Metronidazole—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000416	0.000801	CcSEcCtD
Metronidazole—Rash—Vincristine—lymphatic system cancer	0.000414	0.000797	CcSEcCtD
Metronidazole—Dermatitis—Vincristine—lymphatic system cancer	0.000414	0.000796	CcSEcCtD
Metronidazole—Headache—Vincristine—lymphatic system cancer	0.000412	0.000792	CcSEcCtD
Metronidazole—Nausea—Carmustine—lymphatic system cancer	0.000409	0.000787	CcSEcCtD
Metronidazole—Angiopathy—Methotrexate—lymphatic system cancer	0.000407	0.000783	CcSEcCtD
Metronidazole—Vomiting—Mitoxantrone—lymphatic system cancer	0.000407	0.000783	CcSEcCtD
Metronidazole—Immune system disorder—Methotrexate—lymphatic system cancer	0.000405	0.00078	CcSEcCtD
Metronidazole—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000404	0.000778	CcSEcCtD
Metronidazole—Rash—Mitoxantrone—lymphatic system cancer	0.000403	0.000776	CcSEcCtD
Metronidazole—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000403	0.000775	CcSEcCtD
Metronidazole—Headache—Mitoxantrone—lymphatic system cancer	0.000401	0.000771	CcSEcCtD
Metronidazole—Mental disorder—Methotrexate—lymphatic system cancer	0.000393	0.000756	CcSEcCtD
Metronidazole—Erythema—Methotrexate—lymphatic system cancer	0.000391	0.000752	CcSEcCtD
Metronidazole—Nausea—Vincristine—lymphatic system cancer	0.00039	0.000751	CcSEcCtD
Metronidazole—Dysgeusia—Methotrexate—lymphatic system cancer	0.000382	0.000736	CcSEcCtD
Metronidazole—Nausea—Mitoxantrone—lymphatic system cancer	0.00038	0.000731	CcSEcCtD
Metronidazole—Back pain—Methotrexate—lymphatic system cancer	0.000378	0.000727	CcSEcCtD
Metronidazole—Vision blurred—Methotrexate—lymphatic system cancer	0.000368	0.000708	CcSEcCtD
Metronidazole—Malaise—Methotrexate—lymphatic system cancer	0.000352	0.000678	CcSEcCtD
Metronidazole—Vertigo—Methotrexate—lymphatic system cancer	0.000351	0.000675	CcSEcCtD
Metronidazole—Leukopenia—Methotrexate—lymphatic system cancer	0.00035	0.000673	CcSEcCtD
Metronidazole—Convulsion—Methotrexate—lymphatic system cancer	0.000338	0.000651	CcSEcCtD
Metronidazole—Arthralgia—Methotrexate—lymphatic system cancer	0.000333	0.00064	CcSEcCtD
Metronidazole—Chest pain—Methotrexate—lymphatic system cancer	0.000333	0.00064	CcSEcCtD
Metronidazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00033	0.000635	CcSEcCtD
Metronidazole—Confusional state—Methotrexate—lymphatic system cancer	0.000321	0.000618	CcSEcCtD
Metronidazole—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000319	0.000613	CcSEcCtD
Metronidazole—Infection—Methotrexate—lymphatic system cancer	0.000317	0.000609	CcSEcCtD
Metronidazole—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000313	0.000602	CcSEcCtD
Metronidazole—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000312	0.000601	CcSEcCtD
Metronidazole—Skin disorder—Methotrexate—lymphatic system cancer	0.00031	0.000596	CcSEcCtD
Metronidazole—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000308	0.000593	CcSEcCtD
Metronidazole—Anorexia—Methotrexate—lymphatic system cancer	0.000304	0.000585	CcSEcCtD
Metronidazole—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00029	0.000559	CcSEcCtD
Metronidazole—Insomnia—Methotrexate—lymphatic system cancer	0.000288	0.000555	CcSEcCtD
Metronidazole—Paraesthesia—Methotrexate—lymphatic system cancer	0.000286	0.000551	CcSEcCtD
Metronidazole—Somnolence—Methotrexate—lymphatic system cancer	0.000283	0.000545	CcSEcCtD
Metronidazole—Dyspepsia—Methotrexate—lymphatic system cancer	0.000281	0.00054	CcSEcCtD
Metronidazole—Decreased appetite—Methotrexate—lymphatic system cancer	0.000277	0.000533	CcSEcCtD
Metronidazole—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000275	0.00053	CcSEcCtD
Metronidazole—Fatigue—Methotrexate—lymphatic system cancer	0.000275	0.000529	CcSEcCtD
Metronidazole—Pain—Methotrexate—lymphatic system cancer	0.000273	0.000525	CcSEcCtD
Metronidazole—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000263	0.000505	CcSEcCtD
Metronidazole—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000261	0.000502	CcSEcCtD
Metronidazole—Urticaria—Methotrexate—lymphatic system cancer	0.000253	0.000487	CcSEcCtD
Metronidazole—Abdominal pain—Methotrexate—lymphatic system cancer	0.000252	0.000485	CcSEcCtD
Metronidazole—Body temperature increased—Methotrexate—lymphatic system cancer	0.000252	0.000485	CcSEcCtD
Metronidazole—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000235	0.000452	CcSEcCtD
Metronidazole—Asthenia—Methotrexate—lymphatic system cancer	0.000229	0.00044	CcSEcCtD
Metronidazole—Pruritus—Methotrexate—lymphatic system cancer	0.000226	0.000434	CcSEcCtD
Metronidazole—Diarrhoea—Methotrexate—lymphatic system cancer	0.000218	0.00042	CcSEcCtD
Metronidazole—Dizziness—Methotrexate—lymphatic system cancer	0.000211	0.000406	CcSEcCtD
Metronidazole—Vomiting—Methotrexate—lymphatic system cancer	0.000203	0.00039	CcSEcCtD
Metronidazole—Rash—Methotrexate—lymphatic system cancer	0.000201	0.000387	CcSEcCtD
Metronidazole—Dermatitis—Methotrexate—lymphatic system cancer	0.000201	0.000386	CcSEcCtD
Metronidazole—Headache—Methotrexate—lymphatic system cancer	0.0002	0.000384	CcSEcCtD
Metronidazole—Nausea—Methotrexate—lymphatic system cancer	0.000189	0.000364	CcSEcCtD
